Dexcom (DXCM) Gets a Buy Rating from Leerink Partners

Leerink Partners analyst Danielle Antalffy maintained a Buy rating on Dexcom (DXCMResearch Report) on January 24 and set a price target of $500.00. The company’s shares closed last Thursday at $442.27.

According to, Antalffy is a 4-star analyst with an average return of 9.1% and a 52.0% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Inspire Medical Systems, and Treace Medical Concepts.

Currently, the analyst consensus on Dexcom is a Strong Buy with an average price target of $580.89, a 33.8% upside from current levels. In a report issued on January 31, Oppenheimer also maintained a Buy rating on the stock with a $580.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Dexcom’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $650 million and net profit of $70.9 million. In comparison, last year the company earned revenue of $501 million and had a net profit of $72.2 million.

Based on the recent corporate insider activity of 124 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DXCM in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

California-based DexCom, Inc. is a medical device manufacturing company. The company designs, develops and focuses on commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes. Its products include DexCom G4 PLATINUM System, DexCom G5 Mobil, DexCom G6, and DexCom Share.

Read More on DXCM:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More